Compare PEN & ARCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PEN | ARCC |
|---|---|---|
| Founded | 2004 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.9B | 12.8B |
| IPO Year | 2015 | 2004 |
| Metric | PEN | ARCC |
|---|---|---|
| Price | $332.42 | $19.09 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 10 |
| Target Price | ★ $357.33 | $21.50 |
| AVG Volume (30 Days) | 503.4K | ★ 7.0M |
| Earning Date | 04-30-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 10.22% |
| EPS Growth | ★ 1155.56 | N/A |
| EPS | ★ 4.52 | 1.86 |
| Revenue | ★ $1,403,665,000.00 | N/A |
| Revenue This Year | $14.34 | $5.77 |
| Revenue Next Year | $13.71 | $2.29 |
| P/E Ratio | $73.38 | ★ $10.11 |
| Revenue Growth | ★ 17.50 | N/A |
| 52 Week Low | $221.26 | $17.40 |
| 52 Week High | $362.41 | $23.42 |
| Indicator | PEN | ARCC |
|---|---|---|
| Relative Strength Index (RSI) | 47.90 | 60.59 |
| Support Level | $326.58 | $18.78 |
| Resistance Level | $338.99 | $20.28 |
| Average True Range (ATR) | 2.20 | 0.39 |
| MACD | 0.43 | 0.17 |
| Stochastic Oscillator | 63.10 | 92.22 |
Penumbra Inc is a thrombectomy company focused on developing technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism (including pulmonary embolism), and acute limb ischemia. Its portfolio includes Computer-Assisted Vacuum Thrombectomy (CAVT), which is designed to remove blood clots throughout the body. The company offers products such as the Artemis Neuro Evacuation Device (used for surgical removal of fluid and tissue from the ventricles and cerebrum), Indigo System, Penumbra System Reperfusion Catheter, LANTERN Delivery Microcatheter, Penumbra Smart Coil, and ACE Reperfusion Catheters, among others. The company generates maximum revenue from the sale of its products in the United States, followed by international markets.
Ares Capital Corp is a United States-based closed-ended specialty finance company. Its investment objective is to generate both current income and capital appreciation through debt and equity investments. The company focuses on investing in first lien senior secured loans (including unitranche loans, which are loans that combine both senior and subordinated debt, generally in a first lien position) and second lien senior secured loans. In addition to senior secured loans, the company also invests in subordinated loans and preferred equity, it also makes common equity investments.